NHD Global
Growth Hormone & IGF · Source-reviewed dossier
Source-Reviewed Research Dossier
Hexarelin is a synthetic growth-hormone secretagogue peptide studied at the ghrelin receptor and in cardiovascular models. Much of the claimed cardiac literature is mechanistic or animal-based rather than controlled human outcome evidence.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A focused review describes GH-dependent and GH-independent cardiovascular hypotheses for hexarelin.
Review-level mechanisms do not establish clinical efficacy.
Read the primary studyA 2023 study reported apoptosis-related outcomes in an ischemic acute-kidney-injury model.
The experiment does not support human treatment or catalog-lot claims.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Review-level mechanisms do not establish clinical efficacy.
View primary recordThe experiment does not support human treatment or catalog-lot claims.
View primary recordThird-party publications selected for direct relevance.
Mao Y, et al. Journal of Geriatric Cardiology. 2014. PMID 25278975.
Preclinical study. 2023. PMID 37710348.
Concise answers for researchers comparing identity, evidence and catalog variants.
Hexarelin is a synthetic growth-hormone secretagogue peptide studied at the ghrelin receptor and in cardiovascular models. Much of the claimed cardiac literature is mechanistic or animal-based rather than controlled human outcome evidence.
The public evidence is dominated by reviews and preclinical cardiovascular or renal models.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
Hexarelin has controlled human pharmacology data, but the central evidence is an acute 12-person GH dose-response experiment rather than a clinical-outcome trial.
Updated September 8, 2026
Hexarelin, also called Examorelin, is an amidated synthetic hexapeptide. The 2-methyl substitution on D-tryptophan distinguishes it from related GHRPs.
Updated September 8, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: HX2 · 2 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
